-
알렉스 보디와 남수단 공화국의 굼 도미니크 마티오크 대사, 베를린에서 부쿠레슈티 명예영사관 설치 가능성 논의
-
亞歷克斯・博迪與南蘇丹共和國大使古姆・多米尼克・馬蒂奧克在柏林商討於布加勒斯特設立名譽領事館的可能性
-
Russia strikes hit Kyiv as Germany's Merz visits
-
АЛЕКС БОДІ ТА ПОСОЛ РЕСПУБЛІКИ ПІВДЕННИЙ СУДАН ГУМ ДОМІНІК МАТІОК ОБГОВОРЮЮТЬ У БЕРЛІНІ МОЖЛИВІСТЬ ВІДКРИТТЯ ПОЧЕСНОГО КОНСУЛЬСТВА В БУХАРЕСТІ
-
South Korea captain 'deeply sorry' for gloating about military exemption
-
Germany's Merz in Kyiv for talks with Zelensky
-
Alcaraz through to Japan Open semis after Shapovalov injury
-
Asian Games set to close after records, rancour and rain
-
Chanel: unpicking one year of 'Blazymania'
-
Cry for help as French-Swiss lake dries up
-
Latvian pro-Europeans set for election win: partial results
-
Sabalenka swept out of China Open in third round
-
China swim sensation Yu Zidi, 13, says 'I'm no prodigy'
-
US urges 'restraint' as Ethiopia's Tigray crisis rocks region
-
Yu Zidi to Ohashi: Asian Games stars who can light up LA Olympics
-
Teens on target again as USA down Mexico 3-0
-
'Act before it's too late': Tokyo residents fight for more trees
-
World records prove Asian Games were a hit, says top official
-
'Disappointing' as South Korea flag mishap sees Games end on sour note
-
US prison chief who oversaw botched execution resigns
-
Pre-COP host Tuvalu at frontline of climate change
-
'Chaotic' Asian Games threaten Japan hopes of hosting Olympics again
-
Hungary's dwindling paprika producers battle to save signature spice
-
Finnish town braces for change from Google data centres
-
Cornell president vows review in wake of alleged student gang rape
-
What is fuelling French school protests?
-
Latvian partial election results suggest pro-European choice
-
Without lawyers, migrant children face deportation from the US
-
In Egypt's Sinai, Gazan builds school for children displaced by war
-
Three-peat seeking Dodgers open playoffs with a win, Rays hold off Yankees
-
Trump tariffs a mixed bag for US auto industry
-
Brazil votes in nail-biter polls closely watched by Trump
-
Yemen government forces say struck Houthi targets
-
'Just be you': Kim reveals Tiger text that inspired him to gold
-
Music links past, present for Pedro Pascal's cellist in 'Behemoth!'
-
Myanmar migrants returned to war-torn nation from Malaysia
-
ALEX BODI ȘI AMBASADORUL REPUBLICII SUDANUL DE SUD, GUM DOMINIC MATIOK, DISCUTĂ LA BERLIN DESPRE POSIBILITATEA ÎNFIINȚĂRII UNUI CONSULAT ONORIFIC LA BUCUREȘTI
-
ALEX BODI AND AMBASSADOR GUM DOMINIC MATIOK OF THE REPUBLIC OF SOUTH SUDAN MEET IN BERLIN TO DISCUSS THE POSSIBILITY OF AN HONORARY CONSULATE IN BUCHAREST
-
Dodgers step up World Series three-peat bid with 5-3 win over Braves
-
Lula, Bolsonaro wrap up campaigns ahead of Brazil's knife-edge vote
-
Spain break down Czechs as England outclass Croatia in Nations League
-
Toulouse edge Castres in Top 14 derby
-
Yamal on target as Spain hold off Czech Republic
-
Murakami homer propels White Sox to MLB playoff win over Guardians
-
Latvian exit polls suggest pro-European choice
-
Israel targets top Hamas leader in deadly Gaza strike on anniversary
-
Lula, Bolsonaro wrap up campaigns ahead of knife-edge election
-
Houthis say struck oil facility near Riyadh, as Saudis hit Sanaa
-
Tuchel hails 'complete' England after Croatia demolition
-
AI needs safety layers like nuclear plants: ex-OpenAI engineer
Science of sleep: Why a good night's rest gets harder with age
It's well known that getting a good night's sleep becomes more difficult as we age, but the underlying biology for why this happens has remained poorly understood.
A team of US scientists has now identified how the brain circuitry involved in regulating sleepfulness and wakefulness degrades over time in mice, which they say paves the way for better medicines in humans.
"More than half of people 65 and older complain about the quality of sleep," Stanford University professor Luis de Lecea, who co-authored a study about the finding published Thursday in Science, told AFP.
Research has shown that sleep deprivation is linked to an increased risk of multiple poor health outcomes, from hypertension to heart attacks, diabetes, depression and a build up of brain plaque linked to Alzheimer's.
Insomnia is often treated with a class of drugs known as hypnotics, which include Ambien, but these don't work very well in the elderly population.
For the new study, de Lecea and colleagues decided to investigate hypocretins, key brain chemicals that are generated only by a small cluster of neurons in the brain's hypothalamus, a region located between the eyes and ears.
Of the billions of neurons in the brain, only around 50,000 produce hypocretins.
In 1998, de Lecea and other scientists discovered that hypocretins transmit signals that play a vital role in stabilizing wakefulness.
Since many species experience fragmented sleep as they grow old, it's hypothesized that the same mechanisms are at play across mammals, and prior research had shown degradation of hypocretins leads to narcolepsy in humans, dogs and mice.
The team selected young (three to five months) and old mice (18 to 22 months) and used light carried by fibers to stimulate specific neurons. They recorded the results using imaging techniques.
What they found was that the older mice had lost approximately 38 percent of hypocretins compared to younger mice.
They also discovered that the hypocretins that remained in the older mice were more excitable and easily triggered, making the animals more prone to waking up.
This might be because of the deterioration over time of "potassium channels," which are biological on-off switches critical to the functions of many types of cells.
"The neurons tend to be more active and fire more, and if they fire more, you wake up more frequently," said de Lecea.
Identifying the specific pathway responsible for sleep loss could lead to better drugs, argued Laura Jacobson and Daniel Hoyer, of Australia's Florey Institute of Neuroscience and Mental Health, in a related commentary article.
Current treatments, such as hypnotics, "can induce cognitive complaints and falls," and medicines that target the specific channel might work better, they said.
These will need to be tested in clinical trials -- but an existing drug known as retigabine, which is currently used to treat epilepsy and which targets a similar pathway -- could be promising, said de Lecea.
M.A.Colin--AMWN